Dutch Colorectal Cancer Group
12
3
4
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
8.3%
1 terminated/withdrawn out of 12 trials
83.3%
-3.2% vs industry average
83%
10 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Prospective Data Collection Initiative on Colorectal Cancer
Role: lead
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases
Role: lead
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
Role: collaborator
A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
Role: collaborator
Radioembolization in Elderly/ Fragile Patients With mCRC
Role: collaborator
The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer
Role: lead
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
Role: lead
Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)
Role: lead
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
Role: lead
Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma
Role: lead
Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer
Role: lead
Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma
Role: lead
All 12 trials loaded